These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 21663429)

  • 1. Differential effects of predictors on methylphenidate initiation and discontinuation among young people with newly diagnosed attention-deficit/hyperactivity disorder.
    Chen CY; Yeh HH; Chen KH; Chang IS; Wu EC; Lin KM
    J Child Adolesc Psychopharmacol; 2011 Jun; 21(3):265-73. PubMed ID: 21663429
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Continuity of methylphenidate treatment for attention-deficit/hyperactivity disorder.
    Marcus SC; Wan GJ; Kemner JE; Olfson M
    Arch Pediatr Adolesc Med; 2005 Jun; 159(6):572-8. PubMed ID: 15939858
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Attention-deficit/hyperactivity disorder, methylphenidate use and the risk of developing schizophrenia spectrum disorders: A nationwide population-based study in Taiwan.
    Shyu YC; Yuan SS; Lee SY; Yang CJ; Yang KC; Lee TL; Wang LJ
    Schizophr Res; 2015 Oct; 168(1-2):161-7. PubMed ID: 26363968
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drug treatment patterns of attention-deficit/hyperactivity disorder in children and adolescents in Germany: results from a large population-based cohort study.
    Garbe E; Mikolajczyk RT; Banaschewski T; Petermann U; Petermann F; Kraut AA; Langner I
    J Child Adolesc Psychopharmacol; 2012 Dec; 22(6):452-8. PubMed ID: 23234588
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Testicular Function After Long-Term Methylphenidate Treatment in Boys with Attention-Deficit/Hyperactivity Disorder.
    Wang LJ; Lee SY; Chou WJ; Lee MJ; Tsai CS; Lee TL; Yang CJ; Yang KC; Chen CK; Shyu YC
    J Child Adolesc Psychopharmacol; 2019 Aug; 29(6):433-438. PubMed ID: 30575416
    [No Abstract]   [Full Text] [Related]  

  • 6. Predictors of weight loss in children with attention deficit hyperactivity disorder treated with stimulant medication.
    Schertz M; Adesman AR; Alfieri NE; Bienkowski RS
    Pediatrics; 1996 Oct; 98(4 Pt 1):763-9. PubMed ID: 8885958
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of methylphenidate formulation for attention deficit hyperactivity disorder on patterns and outcomes of treatment.
    Lage M; Hwang P
    J Child Adolesc Psychopharmacol; 2004; 14(4):575-81. PubMed ID: 15662149
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment persistence in attention deficit/hyperactivity disorder: a retrospective analysis of patients initiated on lisdexamfetamine vs other medications.
    Setyawan J; Guérin A; Hodgkins P; Gauthier G; Cloutier M; Wu E; Erder MH
    J Med Econ; 2013 Nov; 16(11):1275-89. PubMed ID: 24004347
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Developing a Risk Score to Guide Individualized Treatment Selection in Attention Deficit/Hyperactivity Disorder.
    Setyawan J; Yang H; Cheng D; Cai X; Signorovitch J; Xie J; Erder MH
    Value Health; 2015 Sep; 18(6):824-31. PubMed ID: 26409610
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Suicide risk reduction in youths with attention-deficit/hyperactivity disorder prescribed methylphenidate: A Taiwan nationwide population-based cohort study.
    Liang SH; Yang YH; Kuo TY; Liao YT; Lin TC; Lee Y; McIntyre RS; Kelsen BA; Wang TN; Chen VC
    Res Dev Disabil; 2018 Jan; 72():96-105. PubMed ID: 29121517
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An open-label, randomized, active-controlled equivalent trial of osmotic release oral system methylphenidate in children with attention-deficit/hyperactivity disorder in Taiwan.
    Gau SS; Shen HY; Soong WT; Gau CS
    J Child Adolesc Psychopharmacol; 2006 Aug; 16(4):441-55. PubMed ID: 16958569
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term effects of short-acting methylphenidate on growth rates of children with attention deficit hyperactivity disorder at Queen Sirikit National Institute of Child Health.
    Moungnoi P; Maipang P
    J Med Assoc Thai; 2011 Aug; 94 Suppl 3():S158-63. PubMed ID: 22043770
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment outcomes with methylphenidate formulations among patients with ADHD: retrospective claims analysis of a managed care population.
    Hodgkins P; Sasané R; Christensen L; Harley C; Liu F
    Curr Med Res Opin; 2011; 27 Suppl 2():53-62. PubMed ID: 21973231
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics and therapeutic effect of OROS methylphenidate under different breakfast conditions in children with attention-deficit/hyperactivity disorder.
    Wigal SB; Gupta S; Heverin E; Starr HL
    J Child Adolesc Psychopharmacol; 2011 Jun; 21(3):255-63. PubMed ID: 21663428
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Early discontinuation of attention-deficit/hyperactivity disorder drug treatment: a Danish nationwide drug utilization study.
    Pottegård A; Bjerregaard BK; Kortegaard LS; Zoëga H
    Basic Clin Pharmacol Toxicol; 2015 Apr; 116(4):349-53. PubMed ID: 25220739
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of methylphenidate delivery profiles on driving performance of adolescents with attention-deficit/hyperactivity disorder: a pilot study.
    Cox DJ; Merkel RL; Penberthy JK; Kovatchev B; Hankin CS
    J Am Acad Child Adolesc Psychiatry; 2004 Mar; 43(3):269-75. PubMed ID: 15076259
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Better efficacy for the osmotic release oral system methylphenidate among poor adherents to immediate-release methylphenidate in the three ADHD subtypes.
    Chou WJ; Chou MC; Tzang RF; Hsu YC; Gau SS; Chen SJ; Wu YY; Huang YF; Liang HY; Cheng H
    Psychiatry Clin Neurosci; 2009 Apr; 63(2):167-75. PubMed ID: 19335386
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The relationship between symptomatic and functional changes of Korean children and adolescents with attention-deficit/hyperactivity disorder treated with osmotic-controlled release oral delivery system-methylphenidate.
    Kim E; Cheon KA; Joung YS; Kim JY; Song DH
    Clin Neuropharmacol; 2015; 38(1):30-5. PubMed ID: 25580917
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Once-daily multilayer-release methylphenidate in a double-blind, crossover comparison to immediate-release methylphenidate in children with attention-deficit/hyperactivity disorder.
    Weiss M; Hechtman L; Turgay A; Jain U; Quinn D; Ahmed TS; Yates T; Reiz JL; Donnelly GA; Harsanyi Z; Darke AC
    J Child Adolesc Psychopharmacol; 2007 Oct; 17(5):675-88. PubMed ID: 17979587
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Overlapping Prescriptions of Stimulants for Children and Adolescents With Attention-Deficit Hyperactivity Disorder.
    Chen CY; Yeh HH; Fang SY; Wu EC; Chang IS; Lin KM
    Psychiatr Serv; 2012 Oct; 63(10):1011-8. PubMed ID: 22911441
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.